Given that immune checkpoint blockade combined with pemetrexed-platinum doublet chemotherapy has been approved as the standard first-line treatment for lung adenocarcinoma, it will be worth to further evaluate EXO1 rs1047840G>A as a biomarker to predict clinical outcomes of combined immunotherapy and pemetrexed chemotherapy. Here, EXO1 is linked to lung adenocarcinoma.